Skip to content

8-KAccepted Nov 2, 10:50 AM ET

Supernus Pharmaceuticals, Inc.: delisting after Nov 2, 2026 merger

SUPERNUS PHARMACEUTICALS, INC.

Accepted (ET)

10:50 AM

Nov 2, 2026

Filed

Nov 2, 2026

Documents

11

Size

187.7 KB

Summary

Supernus Pharmaceuticals, Inc.: delisting after Nov 2, 2026 merger

Updated

What happened The company reported that, in connection with the consummation of the Merger on Nov 2, 2026, it notified Nasdaq of the completion of the Merger and requested that Nasdaq suspend trading of the Supernus Common Stock, effective prior to the opening of trading on Nov 2, 2026. The company reported that it requested Nasdaq to file with the SEC a Notification of Removal from Listing and/or Registration on Form 25 to effect the delisting of the Supernus Common Stock from Nasdaq and the deregistration of the Supernus Common Stock under Section 12(b) of the Exchange Act.

The company reported that, following the effectiveness of Form 25, it intends to file with the SEC a certification on Form 15 requesting the deregistration of the Supernus Common Stock under Section 12(g) of the Exchange Act and the suspension of the company’s reporting obligations under Sections 13 and 15(d) of the Exchange Act. The company reported that, as a result of the Merger, the Supernus Common Stock will no longer be listed on any national securities exchange.

Key details

  • Merger consummated on Nov 2, 2026.
  • Requested Nasdaq suspend trading of Supernus Common Stock effective prior to the opening of trading on Nov 2, 2026.
  • Requested Nasdaq file Form 25 to delist and deregister the Supernus Common Stock under Section 12(b) of the Exchange Act.
  • Company intends to file Form 15 after Form 25 is effective to deregister under Section 12(g) and suspend reporting under Sections 13 and 15(d) of the Exchange Act.

Why it may matter This 8-K reports Item 3.01: Notice of delisting or failure to satisfy a continued listing rule or standard. Item 3.01 covers the company notifying Nasdaq of the completion of the Merger, requesting suspension of trading, requesting filing of Form 25 to remove listing and deregister under Section 12(b), and the company’s stated intention to file Form 15 to deregister under Section 12(g) and suspend reporting under Sections 13 and 15(d). The filing does not show why the insider traded or why the company acted.

AI-written summary · check the filing